ArticleInternational journal of oncology2018

Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer.

Yuquan Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.